{
  "id": 7565702,
  "title": "MannKind at H.C. Wainwright conference: new launches lift outlook",
  "url": "https://urgent.news/2026/09/15/mannkind-at-h-c-wainwright-conference-new-launches-lift-outlook",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-15T14:10:18.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/mannkind-at-hc-wainwright-conference-new-launches-lift-outlook-93CH-4902027"
  },
  "original_language": "en",
  "account": "MannKind Corporation (MNKD) made several announcements at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, 15 September 2026. The CFO, Chris Prentiss, highlighted the company's rapid business transformation, driven by new product launches and an expanding pipeline. Prentiss stated that the company had entered a new phase following three significant milestones in 2026, but warned that 2027 would focus on building sales momentum, increasing awareness, and reaching run rates. Early enthusiasm was noted for FUROSCIX ReadyFlow, a pediatric launch of Afrezza, and a revised Phase II study for MNKD-201, an inhalable therapy for idiopathic pulmonary fibrosis (IPF). The company is still working towards steady sales, wider reimbursement, and a clearer long-term development strategy. With a market cap of $1.16 billion, MannKind reported $393.63 million in revenue in the past year, marking a 30% growth. Management highlighted three major drivers in 2026: Afrezza's pediatric approval, the acquisition of scPharmaceuticals, and the approval of FUROSCIX ReadyFlow, alongside progress in MNKD-201's Phase II. Early demand for ReadyFlow has been robust, with physician cost and coverage submissions far exceeding the prior on-body infuser pace. The Afrezza pediatric launch targets a small, concentrated group of doctors, potentially simplifying adoption compared to the adult market. MNKD-201 will undergo a redesigned Phase II trial with 153 patients, expected to yield results in the first half of 2028. MannKind stated that 2027 would primarily focus on building sales momentum, raising awareness, and boosting run rates rather than a single revenue milestone. The company did not provide specific revenue figures for 2026 or 2027, but urged investors to monitor net sales, run rates, and peak sales potential for Afrezza and FUROSCIX. Despite operating at a loss of $0.16 per share in 2026, analysts anticipate profitability in 2027, with forecasted earnings of $0.03 per share. The company maintains a gross profit margin of 75%, indicating strong unit economics as it strives for profitability. Additional insights into MannKind's financial outlook can be found in InvestingPro, which provides 10 ProTips and detailed financial metrics. No explicit revenue guidance was offered for 2027. MannKind is exploring various avenues to reduce facility debt, including royalty income, commercial sales, and future business development. Prentiss emphasized the company's position to evaluate future opportunities with a stronger foundation, having achieved all three 2026 catalysts. The pediatric Afrezza approval, covering patients aged 6 and above, has shifted the commercial landscape from the adult market. With a highly concentrated endocrinology field, the pediatric market comprises about 80% of the target doctors across roughly 50 academic centers. Early data reveals swift transitions from bridge access to paid coverage within the second or third prescription. Payer discussions have become more constructive as the product portfolio expands. The company anticipates encouragement from early adoption and is exploring various marketing strategies for 2027 and beyond. FUROSCIX ReadyFlow, an autoinjector version of FUROSCIX, commenced patient dispensation in the week of the conference following approval. Early response has surpassed expectations, with physicians submitting cost and coverage requests several times higher than the prior run rate for the older on-body infuser. Both current and new doctors are now prescribing ReadyFlow. The company identifies hospital discharge and integrated delivery network (IDN) markets as long-term opportunities, though integration into discharge protocols poses a primary challenge. MannKind is collaborating with hospitals to facilitate seamless integration of ReadyFlow to reduce readmissions. Real-world evidence is already underway and should become clearer by year-end. Despite recent positive commercial momentum, the stock trades at $3.61, down nearly 10% over the past week and about 34% for the year, although it has gained 35% over the past six months. InvestingPro suggests the stock may be undervalued, placing it among the platform's Most Undervalued stocks.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Eupraxia Pharmaceuticals at H.C. Wainwright conference: focus on durability",
        "url": "https://urgent.news/2026/09/14/eupraxia-pharmaceuticals-at-h-c-wainwright-conference-focus-on",
        "published": "2026-09-14T18:56:56.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}